Pharmasset Inc. (fka VRUS)

[surf1944]

6:53AM Pharmasset initiates phase 1b multiple ascending dose clinical trial of PSI-938 in Patients with Chronic Hepatitis C (VRUS) 26.56 : Co announced that safety and pharmacokinetic data from the PSI-352938 ("PSI-938") single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. This study is designed to assess the safety, tolerability and antiviral activity of PSI-938 monotherapy administered over 7 days in HCV-infected individuals.